I'm LongbridgeAI, I can summarize articles.William Blair analyst Steven Lichtman initiated a Buy rating on MiniMed (MMED) on September 8, citing attractive valuation and a favorable share-exchange structure with Medtronic. He believes the transaction will help MiniMed become independent while resolving ownership concentration. Despite risks like competition and CMS bidding pressure, the risk-reward profile is deemed favorable. Wells Fargo also maintained a Buy rating with a $26 price target.
William Blair analyst Steven Lichtman has maintained their bullish stance on MMED stock, giving a Buy rating on September 8.
Steven Lichtman has given his Buy rating due to a combination of factors, including the favorable share-exchange structure Medtronic is offering to MiniMed investors at a 7% discount and the anticipated completion of that transaction. He believes the move will help MiniMed transition more fully into an independent entity while resolving the current concentration of ownership in Medtronic’s hands.
Steven Lichtman’s rating is based on the view that MiniMed’s shares remain attractively valued, trading at a notable discount to comparable companies despite the company’s solid product pipeline and recent fundamental progress. While he acknowledges risks such as intense competition, the importance of flawless pipeline execution, and potential pressure from CMS bidding in the pump market, he judges the risk-reward profile as favorable and supportive of a Buy recommendation.
In another report released on September 8, Wells Fargo also maintained a Buy rating on the stock with a $26.00 price target.